Search research articles
Contact Us
Filters
Showing results (451-460 of 738) with videos related to
Page
of 74
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Gynecologic Oncology
|
February 9, 2023
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
Thomas J Herzog, Sandro Pignata, Sharad A Ghamande, et al.
Lancet (London, England)
|
August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Journal of the National Cancer Institute
|
March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Lari Wenzel, Kathryn Osann, Chelsea McKinney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
The New England Journal of Medicine
|
October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
Gynecologic Oncology
|
March 18, 2025
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
Charles A Leath, Wei Deng, Loren K Mell, et al.
The Lancet. Oncology
|
April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
Linda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
Ignace Vergote, Larry J Copeland, Toon Van Gorp, et al.
Page
of 74
Search research articles
Search
Showing results (451-460 of 738) with videos related to
Sort By:
Page
of 74
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Gynecologic Oncology
|
February 9, 2023
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
Thomas J Herzog, Sandro Pignata, Sharad A Ghamande, et al.
Lancet (London, England)
|
August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Journal of the National Cancer Institute
|
March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Lari Wenzel, Kathryn Osann, Chelsea McKinney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
The New England Journal of Medicine
|
October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
Gynecologic Oncology
|
March 18, 2025
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
Charles A Leath, Wei Deng, Loren K Mell, et al.
The Lancet. Oncology
|
April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
Linda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
Ignace Vergote, Larry J Copeland, Toon Van Gorp, et al.
Page
of 74